Osteoclast Stimulatory Transmembrane Protein (OCSTAMP) Mrna Levels and Clinical Variables in Persons with Plasma Cell Myeloma

Ya-Lan Zhou,Jin Lu,Robert Peter Gale,Shen-Miao Yang,Li-Xin Wu,Jin-Lan Li,Ya-Zhen Qin,Yan-Rong Liu,Hao Jiang,Qian Jiang,Xiaohui Zhang,Lan-Ping Xu,Kai-Yan Liu,Xiao-Jun Huang,Guorui Ruan
DOI: https://doi.org/10.1182/blood-2018-99-116883
IF: 20.3
2018-01-01
Blood
Abstract:Background Bone disease is an important determinant of quality-of-life and survival of persons with plasma cell myeloma (PCM). Biomarkers of bone disease could be useful to predict risk and monitor therapy. In our prior analyses OCSTAMP (osteoclast stimulatory trans-membrane protein) mRNA levels were identified as increased above normals in persons with PCM. OCSTAMP encodes a membrane-anchored cell surface receptor promoting nucleation of osteoclasts involved in bone resorption and osteoclast differentiation.
What problem does this paper attempt to address?